Topical P-gp Inducers for CIPN and Alopecia Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chemotherapy-induced peripheral neuropathy (CIPN) and hair loss (alopecia) are significant side effects of cytotoxic anticancer drugs like paclitaxel, vincristine, and bortezomib, impacting patient quality of life and treatment efficacy.
Innovation Solution
Topical application of P-gp and MRP1 inducers, such as rifampicin, before chemotherapy to increase the expression of these transporters in sensory neurons and hair follicles, reducing chemotherapy accumulation and preventing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic anticancer drugs are administered to treat cancer, then treatment efficacy is improved, but chemotherapy-induced peripheral neuropathy and hair loss occur
Solution Approach 1:
The patent applies preliminary action by topically administering P-gp and MRP1 inducers (such as rifampicin, carbamazepine, or dexamethasone) to the skin before chemotherapy treatment. This pretreatment induces the expression and activity of P-gp and MRP1 transporters in sensory neurons and hair follicles, creating a protective mechanism that reduces chemotherapy accumulation in these tissues before the cytotoxic drugs are administered systemically.
Solution Approach 2:
The patent uses P-gp and MRP1 inducers as intermediary substances that mediate between the chemotherapy drugs and vulnerable tissues. These inducers activate endogenous efflux transporters (P-gp and MRP1) that act as protective intermediaries, pumping chemotherapy drugs out of sensory neurons and hair follicles, thereby reducing toxic accumulation while allowing the chemotherapy to maintain its anticancer efficacy.
2Productivity
If higher doses of chemotherapy are administered to improve treatment success, then treatment success is improved, but side effects like CIPN increase in severity
Solution Approach 1:
The patent applies local quality by creating a localized protective effect in specific tissues (sensory neurons and hair follicles) through topical application of P-gp and MRP1 inducers to the skin. This induces high levels of efflux transporter expression specifically in the pretreated areas, creating a spatial gradient of protection where chemotherapy is actively pumped out of vulnerable cells in the skin and underlying tissues, while systemic chemotherapy doses can be maintained or increased to improve overall treatment success.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces the severity and risk of CIPN and alopecia by enhancing chemotherapy efflux from cells, allowing higher chemotherapy doses and improving treatment tolerability.
Implementation Method 1
P-gp and MRP1 are efflux transporters that pump substrates out of cells
Data Source
AI summary
The present invention relates to compositions comprising a P-gp inducer, for topical use in preventing one or more side effects of chemotherapeutics, which chemotherapeutics are transported out of cells by P-gp. Especially chemotherapy-induced peripheral neuropathy (CIPN) is a relevant side effect to treat/avoid, since CIPN may be a dose limiting side effect of chemotherapy. The invention also relates to kits and to cancer treatment of a subgroup of patients, which subgroup has been topically pretreated with a P-gp inducer.